
Bern Pollock uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
One prostate cancer combination is awaiting an FDA decision this year, and several late-stage trials could produce the next filings. Here's what to watch.
Prostate cancer had a strong summer at the FDA, with two approvals in June and July that moved targeted and radioligand therapy earlier in the disease. So what's next? One combination is under active FDA review with a decision expected before the end of the year, and several phase 3 trials are due to read out in the months ahead. Here is where things stand as of early September.






